The Role of One- and Two-Dimensional Electrophoretic Techniques in Proteomics of the Lung by Viglio, Simona et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
The Role of One- and Two-Dimensional Electrophoretic
Techniques in Proteomics of the Lung
Simona Viglio, Maddalena Cagnone,
Laurent Chiarelli, Roberta Salvini and Paolo Iadarola
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.75042
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Simona Viglio, Maddalena Cagnone, 
Laurent Chiarelli, Roberta Salvini and 
Paolo Iadarola
Additional information is available at the end of the chapter
Abstract
The current chapter was designed to keep the reader informed about the present status of 
pulmonary proteome. Taken together, the results documented here demonstrate that, after 
a decade of activity, proteomics of pulmonary diseases is catching up with its promise. The 
constantly growing number of reports in this area supports the view of this approach as 
one of the decisive methodological tools for the identification/characterization of disease-
associated proteins. In terms of experimental procedures, the basic options available for 
proteomic investigations consist in the identification of proteins through the use of gel-
based or gel-free techniques followed by MS. Obviously, the question arises of whether 
sophisticated technologies (such as the non-gel-based proteomic procedures) may currently 
be more fruitful, in terms of candidate protein marker identification, than “conventional” 
(read electrokinetic) approaches. In light of the versatility and high degree of reproduc-
ibility shown by these new potent strategies, a positive answer is perhaps not surprising. 
Nevertheless, as documented in this chapter, despite being less sophisticated than compet-
ing ones, gel-based techniques still represent a widely used procedure able to generate a 
reliable protein “fingerprint” and to produce qualitative and quantitative information on 
the protein patterns of a variety of human fluids.
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1. Introduction
The changes of the research strategy in the biochemical field driven by technological advancements 
occurred in these years allowed proteomics to progress and become one of the most captivating 
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branches of biochemistry. It is no exaggeration to say that, thanks to the significant step forward in 
the sensitivity and specificity of analytical methods, (almost) all proteins expressed by an organism 
can be detected/quantified even in extremely complex biological matrices. The monitoring of pro-
tein expression patterns in clinical specimens may indeed offer great opportunities to establish sets 
of biomarkers potentially associated with a specific disease status [1–8]. Despite these advantages, 
the question arises whether the application of these sophisticated proteomic procedures have pro-
foundly affected the study of human diseases. If the number of publications in this field counts for 
something, the answer is undoubtedly positive. Through its ability to provide insights into both 
specific and system-level changes in cell, tissue and human physiology, proteomics has driven the 
progress observed in the last years in the elucidation of a variety of multifactorial pathological con-
ditions, including less commonly diagnosed disorders [9–13]. In clinical proteomics several tissues 
and/or biological fluids are routinely analyzed for expressed proteins. Obviously, to make these 
analyses quantitative and reproducible, reliable profiling procedures should be established. Such 
procedures must rely on efficient and robust separation systems whose pivotal role is to make 
the complexity of mixtures simpler. Electrophoretic separations, both in-gel (1-DE and 2-DE) and 
in-solution (capillary electrophoresis (CE) and liquid chromatography (LC) approaches, both cou-
pled to mass spectrometry (MS)), are currently the most attractive strategies toward the separation 
of hundreds/thousands of proteins. While acknowledging a remarkable success of electrophoretic 
approaches over the years, their intrinsic limitations cannot be hushed up. For example, the poor 
(if any) resolution of hydrophobic membrane proteins or of proteins that are too basic/acidic or too 
large/small is a well-known limit of 2-DE. The high protein amount required, the long time needed 
to run the samples, and the difficulty in automating the whole system are additional potential 
drawbacks of these techniques. The advent of LC-based procedures, characterized by unquestion-
able advantages, seemed to mark the fate of electrokinetic methods in the proteomic area. Being a 
bit of years elapsed, it can be argued that, despite the strong competition with LC, gel-based tech-
niques do not appear to have lost this “struggle” yet [14–17]. Electrokinetic approaches, in fact, not 
only maintain their position but also still possess numerous characteristics currently unmatched 
by other proteomic methodologies. 2-DE approaches in fact remain the conventional procedure 
applied to the differential (control vs. diseased case) analysis of biological samples [18–24].
2. Outline of the chapter
The aim of this chapter is to illustrate the potential of electrokinetic procedures to the investi-
gation of a variety of acute and chronic lung disorders. Why focus on pulmonary disorders? 
First, because lung diseases, which involve tens of million people, are some of the most com-
mon medical conditions in the world. Second, while few proteomic studies had been specifi-
cally designed to address this topic in the past, the depth of analysis ultimately reached by 
current procedures provides a new and larger context for future studies on the biology of 
these pathologies. This has allowed for the generation of protein profiles that are useful for 
exploring protein-based pathological mechanisms and/or discovering new potential thera-
peutic targets for a variety of pulmonary disorders.
Each paragraph of this chapter will address the proteomic data relative to a specific lung disease. 
Given that proteomic studies on pulmonary disorders have been carried out mostly on bioflu-
ids, the chapter will focus on the protein profiles obtained from serum/plasma, bronchoalveolar 
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lavage fluid, exhaled breath condensate, sputum and urine of individuals with asthma, inter-
stitial lung disease (ILD), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), 
and other “minor” pathologies. Since different fluids may serve as a rich source of information 
for the same disorder, specific subsections inside each paragraph have been dedicated to the 
presentation of the proteomic results relative to a peculiar fluid.
Given the hugeness of the subject, proteomics of lung cancer has thoroughly been investi-
gated and greatly acknowledged elsewhere. In keeping with this large deal of literature, this 
topic would require a chapter dedicated, and it was intentionally left out of this chapter.
3. Principles of electrokinetic procedures
Since electrokinetic approaches play a pivotal role throughout the whole chapter, a few details 
about the principles of techniques cited in the following paragraphs will be given here. The term 
“electrokinetics” refers to the motion of charged particles by an applied electrical field. The stan-
dard laboratory technique by which charged molecules migrate through a porous matrix which 
Figure 1. Representative examples of 1-DE, 2-DE, 2D-DIGE, and CE: panels A, B, C, and D, respectively (unpublished 
results from our laboratory).
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behaves like a molecular sieve is electrophoresis. Polyacrylamide is an ideal support for separat-
ing most proteins; under denaturing/reducing conditions and with a discontinuous buffer sys-
tem, one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
or 1-DE is the most widely used electrophoretic technique separating proteins primarily by mass. 
When the ionic detergent SDS binds to proteins, they assume a uniform negative charge. Upon 
application of a current, all SDS-bound proteins in the sample will migrate toward the positive 
electrode, and, because of the sieving effect of the gel matrix, proteins with less mass split from 
those with greater mass because they travel more quickly. When the mixture of proteins is very 
complex, higher resolution may be obtained by applying a two-dimensional (2-DE) procedure 
which separates proteins according to their isoelectric point in the first dimension followed by an 
orthogonal separation via SDS-PAGE in the second one. Similar to 2-DE is two-dimensional dif-
ference gel electrophoresis (2D-DIGE) in which, however, two or more samples are labeled with 
different fluorescent dyes and separated on the same gel, thus eliminating gel-to-gel variability. 
An instrumental evolution of the abovementioned electrophoretic techniques is capillary elec-
trophoresis (CE) in which separation occurs in fused-silica capillaries and separation of proteins 
involves application of high voltages across buffer-filled capillaries. Once separated by electro-
phoresis, gel bands/spots are excised and proteins extracted for analysis by mass spectrometry.
Representative examples of 1-DE, 2-DE, 2D-DIGE, and CE are shown in Figure 1 (panels A, 
B, C, and D, respectively).
4. Asthma
Asthma is an airway disease originating from complex interactions between genetic factors and 
environmental agents. It affects over 300 million people around the world and is characterized 
by airflow limitation resulting in shortness of breath. Bronchial obstruction is extremely vari-
able and often reversible in asthma. Being a global health problem, tools which allow its early 
diagnosis, monitoring, and follow-up would offer great advantages for a better insight into 
its physiopathology. The articles discussed in the following sections prove that the proteomic 
content of sputum/induced sputum and BALf may allow for the identification of specific bio-
markers in asthma.
4.1. Sputum/induced sputum
2-DE coupled to MALDI/TOF allowed Lee et al. [25] to compare the proteomic profiles of spu-
tum from patients with neutrophilic-type uncontrolled asthma (UA) and from patients with 
neutrophilic controlled asthma (CA). It could be observed that, while a few proteins (includ-
ing calgranulin S100A9) were overexpressed in sputum of UA patients, others, associated with 
inflammation, anti-inflammation, enzymatic activity, and immunity signaling, were down-
regulated. Differences in protein abundance and composition between asthma and rhinitis 
were revealed by the proteomic approach (2D-DIGE and MS) applied by Suojalehto et al. [26] 
to induced sputum (IS) and nasal lavage fluid (NLF) of patients. Their findings showed that 
(i) fatty acid-binding protein 5 (FABP5) was upregulated in IS of asthmatics, (ii) vascular endothe-
lial growth factor (VEGF) was increased in NLF of asthmatics, and (iii) in NLF of these subjects, 
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FABP5 and VEGF were positively correlated with cysteinyl leukotriene (CysLT). Based on their 
results, the authors hypothesized that, in asthma, FABP5 may contribute to the airway remodel-
ing and inflammation by regulating the levels of CysLTs which, in turn, induce VEGF production.
4.2. Bronchoalveolar lavage fluid
A differential study on BALf of asthmatic individuals was performed by Wu et al. [27] who 
produced the first comprehensive database of BALf proteins. Abundant proteins were depleted 
by immunoaffinity chromatography, and all others were separated by 1-DE and identified by 
nano-LC-MS/MS. Chemokines and cytokines and a variety of matrix metalloproteases (MMPs) 
were upregulated in subjects after segmental allergen challenge. Other highly overexpressed 
proteins included pulmonary surfactants and LPLUNC1.
5. Interstitial lung disease
Interstitial lung disease (ILD) describes a collection of more than 200 lung disorders that involve 
inflammation and fibrosis of the alveoli, distal airways, and septal interstitium of the lungs. 
Typically, ILD presents with progressive breathlessness, lung crackles, and a diffusely abnormal 
chest radiograph. This disorder can be caused by long-term exposure to hazardous materials or 
by some types of autoimmune diseases, such as rheumatoid arthritis. In some cases, however, 
the etiology remains unknown. The following sections summarize the latest proteomic stud-
ies aimed at clarifying the pathophysiological mechanisms involved in the development and 
progression of ILD. All recent proteomic studies in this area based on electrokinetic approaches 
have been performed on BALf.
5.1. Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disorder characterized 
by continuous production of extracellular matrix that alters parenchymal lung structure and 
effective gas exchange. Cigarette smoking, exposure to agriculture and farming, livestock, 
wood and metal dust, stone, and silica have been associated with significantly increased risk 
of IPF. The etiopathogenesis of the disease is not completely understood, and the prognosis is 
very poor. In light of this, proteomic studies aimed at the discovery of molecules involved in 
triggering and progression of this disorder could help to a better understanding of its physio-
pathology. As expected, all proteomic approaches to study this disorder which involved the 
use of an electrokinetic procedure have been performed on BALf.
Kim et al. [28] compared by 2-DE and nano-LC-MS/MS the proteomes of BALf from 
patients affected by IPF and healthy subjects. An increase of haptoglobin and a decrease of 
α1-antitrypsin, α1-antichymotrypsin, macrophage capping protein, angiotensinogen, hemo-
globin chain B, apolipoprotein (Apo A-I), clusterin, protein disulfide isomerase A3, immuno-
globulin, and complement C4A were observed in IPF subjects. That a local treatment with Apo 
A-I could be effective against the development of experimental lung fibrosis was shown in 
mice. The main goal of the study performed by Ishikawa and colleagues [29] was to discover 
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new markers for both IPF and chronic obstructive pulmonary disease (COPD). By comparing 
the 1-DE and 2-DE profiles of BALf and IS of IPF and COPD patients with those of controls, 
they showed a reduction in the levels of hemoglobin α (Hbα) and hemoglobin β (Hbβ) mono-
mers and complexes only in IPF patients. Furthermore, MS analyses revealed that a modifica-
tion at Cys 105 (most likely the site involved in complex formation) of Hbα was responsible 
for the lack of the Hbα complexes formation in IPF patients. 2-DE, MS, Western blotting, and 
ELISA were applied by Ohlmeier et al. [30] to lung tissues and BALf of IPF, COPD, and alpha-1 
antitrypsin-deficient (AATD) patients with the aim to investigate the different receptors for 
advanced glycation end product (RAGE) isoforms. Their analyses revealed a decrease of the 
full-length RAGE (FL-RAGE) and its C-terminal processed variant (cRAGE) in the lung tis-
sues of IPF and COPD patients but not in AATD. The endogenous secretory RAGE (esRAGE) 
level was reduced in IPF but remained unchanged in COPD. The 2-DE proteomic study by 
Hara et al. [31] aimed at searching for BALf biomarkers allowing to distinguish IPF from other 
fibrotic interstitial pneumonias. Their study showed that S100A9 protein (or calgranulin B, a 
member of the calcium-binding S100 protein family) was upregulated in IPF patients com-
pared to patients with other fibrotic interstitial diseases and healthy controls. Based on these 
findings, S100A9 was thought to be a good candidate biomarker to discriminate IPF from other 
fibrotic interstitial pneumonias. The research group by Landi et al. [32] used the electrokinetic 
approach to compare the proteome of BALf from patients affected by four interstitial lung 
diseases (sarcoidosis, idiopathic pulmonary fibrosis, pulmonary Langerhans cell histiocytosis, 
fibrosis associated to systemic sclerosis) with that of controls (smokers and nonsmokers). The 
proteins they identified (i.e., plastin 2, annexin A3, 14-3-3ε, and S10A6) could be directly or 
indirectly related to the pathophysiology of the different interstitial lung diseases. The same 
research group compared the profile of BALf proteins from IPF patients, never-smokers, and 
smokers to understand which protein(s) could be potentially related to disease progression 
and pathogenesis. Their findings showed that angiotensin system maturation, renin angio-
tensin-aldosterone system, heme metabolism, coagulation system, response to hypoxia, oxi-
dative stress, and iron transport were the metabolic pathways involved in disorder [33]. The 
same group also investigated the molecular patterns and their variability in familial and spo-
radic IPF patients through a differential proteomic analysis based on 2-DE and MS [34]. It was 
observed that, while in familial IPF, the upregulated proteins were those involved in wound-
ing and immune responses, coagulation system, and ion homeostasis, and those involved in 
the oxidative stress response were upregulated in sporadic IPF.
5.2. Sarcoidosis
Sarcoidosis is a multisystem disorder characterized by the formation of epithelioid cell granu-
lomas. Even though lungs, lymph nodes, and eyes are most commonly involved, any organ or 
system of the body can be affected. Patients with genetic susceptibility undergoing persistent 
exposure to unknown inhaled antigens may develop an excessive immune response medi-
ated by antigen-presenting cells (APC) that can trigger the pathological mechanisms of the 
disease. However, its etiology still remains an enigma and a challenge for researchers and 
clinicians due to its unknown, variegated, and unpredictable presentation. The recent state 
of the art relative to the application of proteomic studies aimed at gaining insights into the 
mechanisms of the disease is reported in this section.
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Silva et al. [35] have used a 2D-based proteomic approach to analyze BALf of patients affected 
by sarcoidosis and chronic beryllium disease (CBD) with the aim of comparing the pro-
tein profiles at the site of active inflammation. Briefly, the differentially expressed proteins 
were highlighted by 2D-DIGE and identified by MALDI-TOF. In accordance with the ongo-
ing chronic inflammation response in lungs of these patients, most of these proteins were 
immune-related proteins.
While being a well-known risk factor for the development of various interstitial lung diseases, 
smoking is generally not related to the occurrence of sarcoidosis. To evaluate better the influ-
ence of cigarette smoking on the proteome of BALf from sarcoidosis patients and to study 
the pathogenetic mechanism of the disease, Landi et al. [36] investigated by 2-DE the protein 
profile and network of BALf from sarcoidosis patients, smokers (SC), and nonsmokers (NSC) 
used as controls. MALDI-TOF MS revealed that 34 spots contained unique proteins involved 
in lipid, mineral, and vitamin D metabolism and immune regulation of macrophage function. 
These findings confirmed that, differently from other ILDs, the expression profile of proteins 
from sarcoidosis patients was more comparable to that of NSC than of SC.
5.3. Lung fibrosis associated with systemic sclerosis
Systemic sclerosis (SSc) is a disease of unknown origin characterized by increased deposition 
of collagen and other extracellular matrix proteins in skin and multiple internal organs. About 
70% of SSc patients develop a severe and progressive lung fibrosis, ILD being the main cause 
of mortality. Nevertheless, the mechanisms involved in the onset and progression of fibrosis 
remains unknown. To clarify the causative role of ILD in SSc, Shirahama et al. [37] analyzed 
the protein profiles of BALf from patients affected by SSc with and without pulmonary fibrosis 
(SSc-fib+ and SSc-fib−). 2-DE combined with MALDI-TOF MS was the method of choice. The 
authors showed that, among other proteins identified, α2-macroglobulin, α1-antitrypsin, and 
pulmonary surfactant protein A were upregulated in SSc-fib+ patients, while α2 heat shock 
protein (HSP) and glutathione S-transferase (GST) were downregulated in the same patients 
compared to SSc-fib ones. These results suggested that these proteins could be potentially 
involved in the development of ILD in SSc patients.
5.4. Rheumatoid arthritis-associated lung disease
Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting 0.5–1.0% of the adult 
population worldwide. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) 
occurs in 10–30% of RA patients and is associated with increased mortality in up to 10% of 
RA patients. The pathogenetic mechanisms of RA-ILD are still unknown. The most common 
pulmonary patterns in RA-ILD are usual interstitial pneumonia (UIP) and nonspecific inter-
stitial pneumonia (NSIP). Nevertheless, the less common organizing pneumonia (OP) and 
lymphocytic interstitial pneumonia are not as rare as hypothesized. The proteomic profiles 
of UIP and OP were compared by Suhara et al. [38] by analyzing BALf of patients with 2-DE 
and nano-LC-ESI-MS/MS. The levels of the fragmented proteins gelsolin and Ig kappa chain 
C region were found to be significantly higher in UIP patients compared to those with an OP 
pattern. Conversely, the levels of α1-antitrypsin, C-reactive protein (CRP), haptoglobin β, and 
surfactant protein A (isoform 5) were significantly higher in the OP than in the UIP patterns. 
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Based on these considerations, the hypotheses were made that (i) identified proteins may play 
a role in the onset and progression of UIP and OP and (ii) fragmented gelsolins may contrib-
ute to the development of pulmonary fibrosis.
5.5. Pulmonary Langerhans cell histiocytosis
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease associated 
with the exposure to tobacco smoke. To provide new insights into its pathogenesis and to 
compare this disorder with COPD, Ghafouri et al. [39] analyzed BALf from a biopsy-proven 
case of PLCH, a COPD patient, and a healthy control. Proteins were separated by 2-DE, and 
their patterns were analyzed with a computerized 2-DE imaging system. If compared with the 
profiles of the COPD patient and the healthy control, that of PLHC patient lacked significant 
amounts of protective and anti-inflammatory proteins. These findings opened a new route for 
a better understanding of the pathophysiology of PLCH.
6. Cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive monogenic disease caused by mutations in the 
gene coding for the CF transmembrane conductance regulator (CFTR) protein. The main 
clinical features of this disorder are progressive bronchiectasis and pancreatic exocrine insuf-
ficiency. Since airway inflammation and recurrent infections leading to respiratory failure 
represent the major causes of morbidity and mortality among CF patients, clinical research is 
mainly focused on these topics. The characterization of proteins from different sources and 
the study of their interactions within the lung microenvironment may be useful tools toward 
the identification of biomarkers for the diagnosis/prognosis of this disorder. The following 
subsections show recent reports on proteomic research in this field.
6.1. Induced sputum
The proteomic approach based on 1-DE, MALDI-TOF-MS, and LC-ESI-MS/MS allowed Schulz 
et al. [40] to analyze high molecular mass proteins in induced sputum from (i) CF adults with and 
without acute exacerbation, (ii) CF children with stable disease and preserved lung function, and 
(iii) healthy adults and children (controls). The main high molecular mass proteins in sputum 
from all subjects investigated were MUC5B and MUC5AC, two mucins that, in exacerbated CF 
adults, seemed degraded and also showed increased sialylation and reduced sulfation/fucosyl-
ation. In addition, while two CF children showed mucin profiles similar to those of exacerbated 
CF adults, the remaining CF children had profiles comparable to those of healthy controls. Based 
on these observations, the authors suggested that the processes of mucin glycosylation and deg-
radation may be considered as predictive biomarkers of lung condition in CF patients.
6.2. Serum
Charro et al. [41] worked on immunodepleted sera of CF patients and of healthy CF and non-
CF carriers. The combination of 2D-PAGE and shotgun LC-MS/MS showed that members of 
the apolipoproteins family were deregulated in CF patients, while heat shock 70 kDa protein 5 
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and the multifunctional enzyme NDKB (an ion sensor in epithelial cells, pancreatic secretion, 
neutrophil-mediated inflammation, and energy production) were identified exclusively in 
the CF group. This interesting comparative study allowed the authors to identify deregulated 
proteins involved in tissue remodeling, complement system dysfunction with consequent 
impairment on defense mechanisms and chronic inflammation, nutritional imbalance, and 
colonization by P. aeruginosa.
7. Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is an “umbrella” term that combines different 
pathological conditions such as emphysema, chronic bronchitis, nonreversible asthma, and 
some types of bronchiectasis characterized by irreversible airflow limitations. Its clinical fea-
tures are a general progressive airflow limitation, destruction of the lung parenchyma, and/
or local fibrosis. Even though the main cause of the disorder is cigarette smoking, continuous 
inhalation of toxic gases and particles which promotes chronic airway inflammation may con-
tribute to its development. COPD can also be determined by genetic factors, i.e., the deficiency 
of α-1 antitrypsin (AATD).
The following subsections describe electrokinetic-based proteomic studies aimed at elucidat-
ing the mechanism underlying the pathobiology of the disease.
7.1. Plasma
To shed new light on the molecular mechanisms of COPD, Merali et al. [42] investigated the 
plasma proteome of 10 COPD patients and 10 healthy controls. Briefly, abundant proteins 
in pooled plasma from each group were immunodepleted; samples were then fractionated 
by 1-DE prior to ESI-MS/MS. A few proteins including acute-phase response proteins, CRP, 
fibrinogen, coagulation factors, and adhesion molecules were upregulated in COPD patients 
compared to controls. By contrast, molecules involved in protease-induced lung tissue injury 
and repair were downregulated.
7.2. Induced sputum
In a proteomic study aimed at identifying proteins involved in COPD pathogenesis, Ohlmeier 
et al. [43] analyzed induced sputum of nonsmokers, smokers, and smokers with moderate 
COPD by cysteine-specific 2D-DIGE coupled with MS. Among other candidates, polymeric 
immunoglobulin receptor (PIGR), a protein involved in specific immune defense and inflam-
mation, appeared upregulated in smokers and subjects with COPD, thus suggesting its pos-
sible role in the regulation of inflammation during COPD pathogenesis.
7.3. Bronchoalveolar lavage fluid
The application of 2-DE followed by LC-MS/MS allowed Plymoth et al. [44] to investigate the 
global proteome of BALf from 29 light and heavy smokers and 18 never-smokers in 6–7 years 
of follow-up study. During this study 7 of the 29 smokers developed moderate COPD. 
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The authors observed that, although protein components were variably expressed in indi-
viduals, inflammatory and redox proteins were unambiguously upregulated in smokers com-
pared to never-smokers.
To elucidate putative molecular mechanisms underlying gender-based differences in the 
pathophysiology of COPD, Kohler et al. [45] applied 2D-DIGE coupled to nano-LC-MS to 
investigate the proteome of non-symptomatic smokers and smokers with COPD. The authors 
observed significant gender differences with a subset of 19 proteins providing a highly pre-
dictive model for classification of female non-symptomatic smokers from female smokers 
with COPD. Subsequent pathway analyses correlated the observed alterations to downregu-
lation of the lysosomal pathway and upregulation of the oxidative phosphorylation pathway. 
No altered proteins were found in the corresponding male classification model.
An interesting research (based on 2-DE and MALDI-TOF/TOF) by Pastor et al. [46, 47] evi-
denced a distinct proteomic reactive oxygen species (ROS) protein signature in BALf from 
COPD and lung cancer patients. Their findings highlight the role of ROS proteins in the 
pathogenic pathways of both diseases and provide new candidate biomarkers and predictive 
tools for lung cancer and COPD diagnosis.
8. Other pulmonary disorders
8.1. Idiopathic pulmonary arterial hypertension
Idiopathic pulmonary arterial hypertension (IPAH) is a rare, life-threatening disorder clini-
cally characterized by sustained elevations of pulmonary artery pressure (PAP). Together 
with intimal proliferation, in situ thrombi, deposition of extracellular matrix, and inflam-
mation, the remodeling of the pulmonary arterial vasculature with medial and adventitial 
thickening of the arteries and arterioles is the main feature of IPAH. This leads to increased 
pulmonary vascular resistance, right heart failure, and death. The latest proteomic studies 
aimed at providing insights into the molecular mechanisms underlying IPAH are presented 
in this section. All recent proteomic studies based on the use of an electrokinetic approach 
have been performed on serum/plasma.
The first proteomic approach aimed at identifying protein changes in serum from IPAH patients 
was performed by Yu et al. [48] by using a combination of 2-DE and MS. The attention of the 
authors was focused on α-1 antitrypsin and vitronectin that, being downregulated in IPAH 
patients, were indicated as proteins involved in the development of the disorder. In fact, while 
the decrease of plasma vitronectin might favor platelet aggregation and thrombus formation, 
the decrease of α-1 antitrypsin might induce apoptosis of endothelial cells resulting in prolifera-
tion of apoptosis-resistant endothelial cell arteriolar occlusion. 2-DE and immunoblotting were 
the combination applied by Terrier et al. [49] to identify the target antigens of antifibroblast 
antibodies (AFAs) in patients affected by IPAH. Among the 21 protein spots specifically rec-
ognized by serum IgG antibodies from IPAH patients, 16 proteins involved in (i) regulation of 
cytoskeletal function, (ii) cell contraction, (iii) oxidative stress, (iv) cell energy metabolism, and 
(v) other key cellular pathways were identified.
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The comparative proteomic analysis based on 2-DE and MALDI-TOF performed by Zhang 
et al. [50] on serum of IPAH patients and controls identified, among other proteins show-
ing significant changes, leucine-rich α-2-glycoprotein (LRG) as a possible specific prognostic 
biomarker of IPAH. 2D-DIGE coupled to MALDI-TOF-MS was used by Yeager et al. [51] to 
investigate the plasma proteome of IPAH children with good and poor outcome to long-term 
vasodilator therapy. Before and after therapy, serum amyloid A (SAA-4) was found to be 
fourfold lower in patients with good outcome compared to those with poor outcome, while 
serum amyloid P (SAP) was 1.3-fold lower prior to therapy in patients with good outcome. 
Since these proteins regulate circulating mononuclear phagocytes, they may contribute to the 
differential response to chronic vasodilator therapy.
8.2. Pulmonary embolism
Pulmonary emboli usually arise from thrombi originating in the deep venous system of the 
lower extremities that travel to the lung and can lodge at the bifurcation of the main pulmo-
nary artery or the lobar causing hemodynamic compromise. Mortality rates in patients with 
acute pulmonary embolism (PE) vary from 1.4 to 17.4% during the first 3 months of treatment. 
The causes of most early deaths are complications such as acute pulmonary arterial hyperten-
sion and right heart failure, whereas medical problems underlying PE are responsible for most 
late deaths. The subsections reported below describe the recent advances in PE proteomics.
8.2.1. Plasma
To identify biomarkers useful for the risk stratification in patients with acute symptomatic 
PE, Insenser et al. [52] studied the plasma proteome of PE patients with low, intermediate, 
and high risk. 2D-DIGE was used to compare the abundance of plasma proteins in the three 
cohorts, and candidate protein markers were identified by MALDI-TOF. Differences among 
patients with different PE severities were observed in a panel of four biomarkers (haptoglo-
bin, hemopexin, α2-macroglobulin, and Ig α-1-chain C region) involved in iron metabolism 
pathways and acute-phase response. Among them, the reduced concentrations of haptoglobin 
could be considered an accurate signal for the biochemical detection of high-risk PE.
8.2.2. Urine
A proteomic approach based on capillary electrophoresis coupled to mass spectrometry (CE-MS) 
was applied by von zur Mühlen et al. [53] for noninvasive identification of PE specific urinary 
markers of pathophysiological relevance. The analysis of urine from patients with symptoms 
associated with deep vein thrombosis and pulmonary embolism (DVT + PE) allowed the authors 
to identify 62 urinary peptides, i.e., fragments of type I collagen and a fragment of fibrinogen 
β-chain, whose presence in organized and acute thrombus has been demonstrated by the authors 
using immunohistochemistry.
Compared to asthma, interstitial lung disease, cystic fibrosis, and COPD, fewer articles have 
been published for “minor” diseases including acute respiratory distress syndrome (ARDS), 
high-altitude pulmonary edema (HAPE), and invasive pulmonary aspergillosis (IPA). This 
is, in large part, due to the lower prevalence of these disorders which results in difficulties 
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recruiting cohorts of patients whose size allows detection of statistically significant data. 
Nevertheless, Chang et al. [54] and Sixt et al. [55] investigated the proteomics of ARDS; pro-
teomic data on HAPE have been published by Ahmad et al. [56, 57] and by Yang et al. [58], 
and preliminary data on IPA have been produced by Brasier et al. [59].
9. Tuberculosis
With more than 10.4 million new cases and about 1.8 million deaths each year, tuberculosis 
(TB) still remains an urgent global health problem. Being all deaths mainly due to the increas-
ing spread of Mycobacterium tuberculosis drug-resistant strains, early diagnosis and treatment 
of infection would be essential for the prevention. However, routine laboratory tests for drug-
resistant TB with sufficient sensitivity and specificity are still not available. This is the rationale 
for the development of electrophoretic-based proteomic approaches aimed at identifying host 
TB-associated proteins or antigens useful for the serodiagnosis of drug-resistant M. tuberculosis 
strains. To better understand and monitor the disease process, Tanaka et al. [60] analyzed 
whole blood supernatants from TB patients by 2D-DIGE followed by MS. Among others, the 
authors observed that retinol-binding protein 4 (RBP4) and fetuin-A were significantly lowered 
in patients with active TB compared to controls, thus suggesting that they could be considered 
potential biomarkers for monitoring the course of the disease during clinical treatment.
Method Advantages/disadvantages Lung disease Matrix Ref. no.
1-DE —Allows separation of all types of proteins, even those 
insoluble in water
—Overlapping of closely spaced bands leading to limited 
resolution
—Often needs the coupling of another detection 
technique, i.e., immunoblotting or MS
Asthma BALf [27]
IPF BALf/IS [29]
CF IS [40]
COPD Plasma [29, 42]
2-DE —Good resolution of protein mixtures
—Allows discernment of posttranslational modifications
—Comparison of multiple gels facilitated by image 
analysis software
—Unable to resolve low molecular weight proteins 
(<10 kDa)
—Presence of high-abundance protein (i.e., albumin, 
immunoglobulin) hiding low-abundance proteins
—Final identification requires spot removal from gels, 
digestion, and peptide analysis by MS
—Low throughput
Asthma IS [25]
IPF BALf [29–34]
Sarcoidosis BALf [32, 35–36]
Lung fibrosis 
associated to SSc
BALf [32, 37]
RA-ILD BALf [38]
PLCH BALf [32, 39]
CF Serum [41]
COPD BALf [29, 30, 44, 
46, 47]
IPAH Serum [48–50]
TB Serum [61]
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Using an immune-proteomic approach based on 2-DE coupled to MALDI-TOF/TOF, Zhang 
et al. [61] analyzed serum from healthy controls and patients infected with drug-resistant or 
drug-susceptible M. tuberculosis strains. By comparing the immune-reactive proteins, the authors 
identified antigens present only in drug-resistant strains. Among the identified immune-reac-
tive proteins, Rv2031c, Rv3692, and Rv0444c had the greater antigenic activity. This feature 
made them possible candidate biomarkers for the serum diagnosis of drug-resistant TB.
The list of proteomic approaches considered in this report, together with their advantages/
disadvantages, the type of pulmonary disorder, the matrix considered, and the original article 
of reference, is shown in Table 1.
10. General considerations
Although the characterization of the full proteome is still challenging, the recent technologi-
cal innovations have improved our ability to obtain cross-sectional time and space snapshots 
of protein levels that reflect observed phenotypes more closely than those of genomic tech-
niques. The current successes in the use of proteomic approaches to understand disease and 
enable drug development resulted in optimism that many more effective diagnostic tests 
Method Advantages/disadvantages Lung disease Matrix Ref. no.
2D-DIGE —Very sensitive
—Ratio of protein expression can be obtained in a single 
gel
—An internal standard can be introduced in each gel 
reducing gel-to-gel variation
—Presence of high-abundance protein (i.e., albumin, 
immunoglobulin) hiding low-abundance proteins
—Unable to resolve low molecular weight proteins 
(<10 kDa)
—Low throughput
—Final identification requires spot removal from gels, 
digestion, and peptide analysis by MS
Asthma Sputum/NLF [26]
COPD IS
BALf
[43]
[45]
IPAH Serum [51]
PE Plasma [52]
TB Serum [60]
CE —Less expensive than LC-MS
—Very small volumes of samples injected (nL)
—Detection of basic and hydrophilic peptides
—Fast separation
—Limited loading capacity
—Unavailability of an integrated system as a marketed 
solution
PE Urine [53]
Table 1. List of proteomic approaches considered in this report together with their advantages/disadvantages, the type 
of pulmonary disorder, the matrix considered, and the original article of reference.
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and treatments tailored to genetic, environmental, and lifestyle factors of individuals will be 
developed. Showing a great ability in providing reference data for the identification of groups 
of individuals who share various attributes, these approaches have opened new opportuni-
ties for the discovery of potential diagnostic/prognostic protein biomarkers in several pul-
monary disorders. By helping researchers in understanding the pathogenesis of respiratory 
diseases and improve patient care, the recent findings have indeed progressively increased 
the interest for the application of proteomics in clinical practice. The current chapter was 
designed to keep the reader informed about the present status of pulmonary proteome. 
Taken together, the results documented here demonstrate that, after a decade of activity, 
proteomics of pulmonary diseases is catching up with its promise. The constantly growing 
number of reports in this area supports the view of this approach as one of the decisive 
methodological tools for the identification/characterization of disease-associated proteins. In 
terms of experimental procedures, the basic options available for proteomic investigations 
consist in the identification of proteins through the use of gel-based or gel-free techniques 
followed by MS. Undoubtedly, the striking improvement in technologies related to accuracy, 
when coupled to quantitative approaches, has a great impact on the quality of the results. 
Obviously, the question arises of whether sophisticated technologies (such as the non-gel-
based proteomic procedures) may actually be more fruitful, in terms of candidate protein 
marker identification, than “conventional” (read electrokinetic) approaches. In light of the 
versatility and high degree of reproducibility shown by these new potent strategies, a posi-
tive answer is perhaps not surprising, at least for one reason. The very high number of pep-
tides identified and quantified results in a higher accuracy, which translates into improved 
alignment and quantification across spectra. Nevertheless, as documented in this chapter, 
despite being less sophisticated than competing ones, gel-based techniques still represent 
a widely used procedure able to generate a reliable protein “fingerprint.” Though it may 
seem nonsense, it is precisely the “limited” amount of information produced by electroki-
netic approaches that may result in an easy interpretation of data. The possibility to compare 
a sample in physiological and pathological conditions allows, in fact, immediate detection of 
possible relevant changes in protein expression which differentiate the two conditions. These 
changes are essential in demonstrating progression from health to disease and understand-
ing the relationship between function and modification. The wide spectrum of examples pre-
sented in this chapter confirms that the application of 1-DE/2-DE/2-DIGE/CE (followed by 
MS) to a variety of biological fluids from individuals with different respiratory diseases may 
result in the production of data with clinical relevance which allow a better understanding 
of the molecular basis of the disorder investigated. However, as it can be observed from the 
data presented in this chapter, while peculiar proteins are pointed out as potential biomark-
ers of specific disorders, a good number of proteins is implicated across a variety of different 
diseases. This makes the notion of a single biomarker to indicate a specific disease more dif-
ficult. For example, while α2-macroglobulin and surfactant protein A have been indicated 
as candidate biomarkers of both lung fibrosis associated with systemic sclerosis and asthma 
[27, 37], the former protein (together with other proteins) was suggested to be also a potential 
biomarker of pulmonary embolism [52]. Indeed, for greater confidence in disease diagno-
sis or prognosis, a suite of biomarkers would provide more specificity than a single one. 
In other words, should the identification of hundreds of candidate biomarkers come at the 
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price of sacrificing their specificity? This discrepancy, however, is only apparent and may be 
reconciled with a harmonization of results. In fact, given that a single molecule can hardly 
discriminate complex processes without context, the finding of common signatures for sev-
eral pulmonary disorders contributes to drawing intriguing parallels among them. This obvi-
ously results in a better understanding of the disease mechanism. On the other hand, the 
fact that several proteins found (e.g., in COPD) have not been reported in other chronic lung 
diseases suggests that the merits of proteomics in hunting down biomarkers with high speci-
ficity cannot be under-evaluated. In this context, the finding of significantly altered levels of 
cathepsin B, ATP synthase, and chaperonin in the BALf of female COPD patients, but not in 
that of males, while supporting the hypothesis that these proteins were the most prominent 
marker candidates for this gender only, confirmed the abovementioned merits of proteomics 
[45]. Proteomic studies have also discovered panels/clusters of oxidant/antioxidant enzymes 
that may be utilized for the assessment of disease severity [44]. Overproduction of ROS can 
also cause oxidative modifications of several important antioxidant/defense enzymes, which 
may be associated with alterations in enzyme conformation, and thus they can function as 
markers of the degree of oxidative stress present in the airways [46, 47]. The huge amount 
of experimental data generated in some cases (i.e., COPD and asthma) represent the first 
attempts to identify the principal pathways involved in the pathogenesis and already allow 
interesting candidate biomarkers to emerge [26, 43].
As the goal of the authors is to offer a broad picture of the subject, readers interested in learn-
ing more about specific techniques or their application to pulmonary diseases are encouraged 
to refer to excellent review articles in this field which show the merits of proteomic techniques 
in producing qualitative and quantitative information on the protein patterns of a variety of 
human fluids/tissues [62–65]. Taken together, these articles represent a good resource which 
describes in depth the status of electrokinetic (and chromatographic) proteomic methods and 
provide a comprehensive picture of proteomics of pulmonary disorders to date.
11. Conclusions
Aside from the interest in deciphering the function of individual proteins, the set of data pro-
duced by proteomic methods represent the starting point for studying large-scale interactions 
that serve to discover general important properties for interaction participation. The fact that 
highly interactive proteins are often well conserved and/or essential or that homologous pro-
teins, and, in particular, proteins with domains from the same family, tend to interact more 
frequently than others will likely improve the knowledge of their intrinsic properties. Thus, 
the understanding of the role these proteins play in the pathogenesis of respiratory diseases, 
while opening the door to much more powerful protein diagnostics, reinforces the linkage 
between basic medical research and clinical laboratory medicine. Addressing these concerns 
is obviously a top priority for the field, the ultimate goal of researchers being to understand 
the biology of disease and to translate this knowledge into the clinic.
There is no doubt that this branch of respiratory proteomics will have substantial improve-
ment in the future.
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